Press release
Investigation announced for Investors in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
An investigation for investors in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares over potential securities laws violations.
Investors who purchased shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Protagonist Therapeutics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Newark, CA based Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. On April 13, 2022, Protagonist disclosed in a filing with the U.S. Securities and Exchange Commission that "[t]he Company has received a letter from United States Food and Drug Administration (the "FDA") indicating the FDA's intent to rescind Breakthrough Therapy Designation for the Company's rusfertide product candidate in polycythemia vera," citing "observed malignancies[.]"
Shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) declined from $38.11 per share on November 15, 2011, to as low as $7.49 per share on May 18, 2022.
Those who purchased shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) here
News-ID: 2629072 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Long-Term Investors in shares of Perpetua Resources …
An investigation was announced concerning possible breaches of fiduciary duties by certain directors and officers of Perpetua Resources Corp.
Investors who are current long term investors in Perpetua Resources Corp. (NASDAQ: PPTA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: PPTA stocks follows a lawsuit filed against Perpetua…
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) Investor Alert: Deadline in Lawsuit …
A deadline is coming up on May 26, 2025 in the lawsuit filed for certain investors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) over alleged securities laws violations by Actinium Pharmaceuticals, Inc.
Investors who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) have certain options and there are strict and short deadlines running. Deadline: May 26, 2025. Actinium Pharmaceuticals, Inc. (NYSE: ATNM) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call…
Investigation announced for Long-Term Investors in shares of Rocket Lab USA, Inc …
An investigation was announced for long-term investors in shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) concerning potential breaches of fiduciary duties by certain directors of Rocket Lab USA, Inc.
Investors who are current long term investors in Rocket Lab USA, Inc. (NASDAQ: RKLB) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
More Releases for Protagonist
Beta-thalassemia (B-thal) Market Segmentation Application, Technology and Market …
The exclusive research report on 'Beta-thalassemia (B-thal) Market' now available with 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬, offers a detailed analysis of the factors influencing the global business sphere. This report also provides precise information pertaining to market size, commercialization aspects and revenue estimation of this business. The report further elucidates the status of leading industry players thriving in the competitive spectrum of the Beta-thalassemia (B-thal) Market.
The research report incorporates a detailed evaluation…
Investigation announced for Investors in Protagonist Therapeutics, Inc. (NASDAQ: …
An investigation was announced over potential breaches of fiduciary duties by certain directors at Protagonist Therapeutics, Inc.
Investors who purchased shares of Protagonist Therapeutics, Inc. (NASDAQ: PTGX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Protagonist Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
Newark, CA based Protagonist…
Global Beta-Thalassemia Market Report 2022, SWOT Analysis and Forecast 2030: Nov …
The global Beta-Thalassemia Market is estimated to be valued at US$ 411.8 million in 2022 and is expected to exhibit a CAGR of 7% over the forecast period (2022-2030).
Market Research, Inc. published a report titled "Beta-Thalassemia Market" research report which covers inclusive data on established trends, drivers, growth opportunities and restraints that can change the market dynamics of the global industry. This report provides an in-depth analysis of the market…
Global Hepcidin Market Insights 2021 – Daiichi Sankyo Co Ltd, Pieris Pharmaceu …
Market Strides' global Hepcidin market research reports cover the market overview-defining the characteristics, scale and growth, segmentation, regional segmentation, competitive landscape, market share, trends and strategies of Hepcidin industries. The market size part gives the market revenue, including historical data of the market and forecasts for the future. The driving factors and constraints of external factors affecting market growth are studied. Industry segmentation subdivides the key sub-sectors that make up…
Hepcidin Market Outlook (2019-2025)| Daiichi Sankyo Co Ltd, Pieris Pharmaceutica …
The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Hepcidin market. It sheds light on how the global Hepcidin Market is expected to grow during the course of the forecast period. With SWOT analysis and Porter’s Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global Hepcidin market and different players operating therein.…
Cyber-Resilience, the Hero Protagonist of the Panda Security Summit and PandaLab …
Chertsey, May 2018
Panda Security, the leading Spanish Company for advanced cybersecurity, held the first occurrence of its Panda Security Summit (#PASS2018) on Friday 18 Mat, in the Goya Theatre in Madrid. The event, which gathered over 400 delegates, comprising CISOs, CIOs and IT Influencers of large companies from Spain, as well as the rest of Europe, served as an analytical framework for the latest cybersecurity trends, both in terms of…
